Onward reported 1H25 results demonstrating positive execution with the company achieving its internal target of selling 30 devices as part of the planned phased launch of the ARC-EX device in the US. We are encouraged to learn that the company expects continued demand for the remainder of the year to meet its FY25 targets (KBCSe: 193 devices). Timelines were reiterated, and we look forward to the home use label expected by YE25, which we view as an important driver for broader commercial uptake ...
Next to a few one-off elements that inflated the headline 1H25 numbers, Ageas noted some strong underlying drivers, leading to several guidance upgrades. Incorporating these elements in our SoTP, we land on a new TP of €62. We feel 1H25 results have underpinned the 27% share rally the stock has seen this year, but we find it harder to see further upside potential at this stage. UK market pricing is again a question mark and BNP & Ethias could cause some negative news flow going forward. Given li...
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025 THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its results for the first half of 2025: Commercial ...
Ackermans & van Haaren s’engage à hauteur de 20 millions de dollars dans le deuxième fonds de Venturi Partners Cher actionnaire, Monsieur, Madame, veuillez trouver ci-joint notre communiqué. Meilleures salutations, Ackermans & van Haaren Pièce jointe
Ackermans & van Haaren investeert 20 miljoen US dollar in het tweede fonds van Venturi Partners Geachte aandeelhouder, Geachte mevrouw, geachte heer, gelieve bijgevoegd ons persbericht te vinden. Met vriendelijke groeten, Ackermans & van Haaren Bijlage
The outlook for 2025 and target FCF to 2027 mostly reflect a much better 1H25 in quantum, but also the confidence that is building up in which problematic areas are being turned around. The UK is looking to integrate in 2H no less than two acquisitions, while China deals with lower interest rates and has upped again its dividends (where AGEAS collects c.25%). Looking ahead, if ETHIAS was to come to the market, the challenge will be to win a bid over banks that will have the Danish compromise cap...
Ackermans & van Haaren: A strong 1H25. Avantium: Nearly there. Eurocommercial Properties: Good results, positive effects of remerchandising. Recticel: Weak 1H25 calls for a 12% downgrade to consensus at Adj. EBITDA level. Sif Group: 2025 and 2026 guidance cuts. Staffing: Belgium - July Temp volume weaker at -3.5% YoY despite easier comps
Ackermans & van Haaren: First-Half 2025 Results Dear shareholder, Dear Madam, Dear Sir, Ackermans & van Haaren publishes today its Half-Year 2025 Results Strong results of core participations support the growth of Ackermans & van Haaren’s H1 2025 profit to 273 million euros (+36%) Record half-year results at DEME, Delen Private Bank, Bank Van Breda and SIPEFSignificant improvement of results at NextensaOutlook (strengthened): net profit for the full-year 2025 is expected to increase by at least 15%Positive net cash position of 431 million euros Please find annexed the full press rel...
Ackermans & van Haaren : Résultats semestriels 2025 Cher actionnaire, Monsieur, Madame, Ackermans & van Haaren publie aujourd'hui ses résultats semestriels pour 2025 Les bons résultats des participations principales soutiennent la croissance du bénéfice d’Ackermans & van Haaren pour le premier semestre 2025, qui atteint 273 millions d’euros (+36%) Des résultats record au premier semestre chez DEME, Delen Private Bank, la Banque Van Breda et SIPEFAmélioration significative des résultats de NextensaPerspectives (relevées): le bénéfice net pour l’ensemble de l’exercice 2025 devrait croît...
Ackermans & van Haaren: Halfjaarresultaten 2025 Geachte aandeelhouder, Geachte mevrouw, geachte heer, Ackermans & van Haaren publiceert zijn halfjaarresultaten 2025: Sterke resultaten van de kernparticipaties steunen de winstgroei van Ackermans & van Haaren in eerste helft 2025 naar 273 miljoen euro (+36%) Record halfjaarresultaten bij DEME, Delen Private Bank, Bank Van Breda en SIPEFAanzienlijke verbetering van de resultaten van NextensaVooruitzichten (versterkt): de nettowinst voor 2025 zal naar verwachting met meer dan 15% stijgenPositieve nettokaspositie van € 431 miljoen Gelieve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.